logo
Plus   Neg
Share
Email

Ark Therapeutics Ink Manufacturing Pact With Laurantis Pharma - Quick Facts

Ark Therapeutics Group Plc (AKT.L) Monday announced that it has been selected to manufacture and supply Lymfactin to Laurantis Pharma under a conditional agreement.

The leading viral product focused contract development and manufacturing services company further stated that it has signed a manufacturing agreement with Laurantis Pharma, a privately held clinical-stage biotechnology company with a broad portfolio of first-in-class products based on two proprietary technologies, for Production of Lymfactin Investigational Treatment for Breast Cancer-Associated Lymphedema.

The Group stated that the agreement is subject to Laurantis receiving regulatory approval to commence its phase I clinical trial. Further, specific terms of the agreement between the two companies have not been disclosed.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Fast-food giant McDonald's said it will be raising hourly wages for more than 36,500 hardworking employees at McDonald's-owned restaurants by an average of 10 percent to make it among the industry-leading pay and benefits package. These increases, which have already begun, will be rolled out over the next several months. Biogen Inc. (BIIB) Friday said its XIRIUS study of cotoretigene toliparvovec failed to meet its primary endpoint in Phase 2/3 in patients with X-linked retinitis pigmentosa or XLRP. The company further noted that the study obtained positive trends in other pre-specified clinically relevant endpoints,... General Mills Inc. (GIS) agreed to buy Tyson Foods' (TSN) pet treats business for $1.2 billion in cash, the companies said in a statement on Friday. The transaction includes the Nudges, Top Chews and True Chews brands. General Mills will also acquire a manufacturing facility in Independence, Iowa.
Follow RTT